Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06052384
Other study ID # RIPH2_PEREZ_DOLOREPIT
Secondary ID 2022-A00919-34
Status Recruiting
Phase N/A
First received
Last updated
Start date December 7, 2023
Est. completion date April 2027

Study information

Verified date December 2023
Source Centre Hospitalier Emile Roux
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

DOLOREPIT is an interventional, RIPH 2, multicenter, randomized, controlled, open-label study comparing two care pathways for the management of patients with chronic pain.


Recruitment information / eligibility

Status Recruiting
Enrollment 664
Est. completion date April 2027
Est. primary completion date April 2027
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - First consultation at the pain management center - Patient with chronic pain as defined by the "Haute Autorité de Santé". The pain must have several of the following characteristics: - Persistence or recurrence - Duration beyond what is usual for the presumed initial cause, especially if the pain has been evolving for more than 3 months; - Inadequate response to treatment; - Important and progressive deterioration of the patient's functional and interpersonal abilities in activities of daily living at home, school, or work due to the pain. - Patients with chronic primary pain (according to the typology defined by the International Classification of Diseases-11) and classified into one of the 4 following categories: - Chronic generalized pain - Complex regional pain syndrome - Chronic primary headache or orofacial pain - Chronic primary musculoskeletal pain - Pittsburgh Sleep Quality Index (PSQI) must be completed by the patient and the score must be available (for randomization purposes) - Have access to an internet connection as a self-administered questionnaire is to complete online, and at least have access to the online platform for CBT treatment if insomnia is detected - Affiliation to a French social security system - Free informed consent Exclusion Criteria: - Patients undergoing cancer treatment or who have completed treatment within the last 2 years - Patient with a chronic inflammatory disease (e.g. rheumatoid arthritis, ankylosing spondylitis, chronic inflammatory bowel disease, Horton's disease, Wegener's disease, myositis, Still's disease, lupus erythematosus, etc.) - Immunocompromised patient - Patient with severe psychiatric pathology that does not allow study follow-up (at the discretion of the investigator) - Patient already treated for a sleep disorder by a sleep specialist (the only prescription of hypnotics is not considered as a criterion of non-inclusion) - Patient follow-up difficult (for geographic motives or other reasons) - Patient under judicial protection of incapable adults or guardianship - Refusal to participate in the research

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Standard pain management combined with sleep disorder management
Standard pain management combined with sleep disorder management at M3, M6, and M12

Locations

Country Name City State
France Centre Hospitalier Emile Roux Le Puy-en-Velay

Sponsors (1)

Lead Sponsor Collaborator
Centre Hospitalier Emile Roux

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary The primary endpoint is the Mental Composite Score (MCS) of the Short Form 36 Health Survey (SF-36) questionnaire It's a scientifically validated multidimensional scale that provides a generic score for assessing quality of life, regardless of pathology, age or gender. The 36 items of this questionnaire evaluate 8 dimensions: physical activity; limitations due to physical condition; physical pain; perceived health; vitality; life and relationships with others; limitations due to physical condition; psychological health, as well as a separate dimension on the evaluation of perceived health compared to one year earlier. An average score range from 0 to 100 and can be calculated according to an established algorithm. A high score means good health and absence of pain. Change from baseline (Day 0) at Month 6 (and at Month 12 only for the experimental group)
Secondary The Physical Composite Score (PCS) of the Short Form 36 Health Survey (SF-36) questionnaire It's a scientifically validated multidimensional scale that provides a generic score for assessing quality of life, regardless of pathology, age or gender. The 36 items of this questionnaire evaluate 8 dimensions: physical activity; limitations due to physical condition; physical pain; perceived health; vitality; life and relationships with others; limitations due to physical condition; psychological health, as well as a separate dimension on the evaluation of perceived health compared to one year earlier. An average score range from 0 to 100 and can be calculated according to an established algorithm. A high score means good health and absence of pain. Change from baseline (Day 0) at Month 6 (and at Month 12 only for the experimental group)
Secondary The score of the French version of the Brief Pain Inventory (BPI). This questionnaire assesses the patient's pain experience and the impact of pain on the patient's daily behavior. It evaluates seven general aspects of the patient's life, divided into fifteen items: activity, mood, walking ability, work, relationships, sleep and enjoyment of life. The score ranges from 0 to 10 with 0 = no pain and 10= worst pain. Change from baseline (Day 0) at Month 6 (and at Month 12 only for the experimental group)
Secondary The score of the French version of the McGill pain questionnaire (MPQ) This questionnaire assesses the sensory and emotional dimensions of the patient's pain. It is composed of sixteen items, the first eight of which characterize pain from a sensory point of view, and the following eight from an affective point of view.
Each item is scored from 0 to 4, with 0 corresponding to "no pain", 1 to "mild pain", 2 to "moderate pain", 3 to "severe pain" and 4 to "extremely severe pain".
Change from baseline (Day 0) at Month 6 (and at Month 12 only for the experimental group)
Secondary The score of Hospital anxiety and depression scale (HADS) This questionnaire can be used to detect anxiety or depression. For each component (seven items for the "anxiety" component and seven items for the "depression" component), the score obtained is analyzed. A score less than or equal to 7 indicates no symptomatology, a score between 8 and 10 indicates doubtful symptomatology, and a score greater than or equal to 11 indicates definite symptomatology. Change from baseline (Day 0) at Month 6 (and at Month 12 only for the experimental group)
Secondary The score of the French version of Pittsburgh Sleep Quality Index (PSQI) This is a generic nineteen-item questionnaire for measuring sleep problems. A PSQI score less than or equal to 5 designates "good sleepers", while a score strictly greater than 5 designates "poor sleepers". Change from baseline (Day 0) at Month 6 (and at Month 12 only for the experimental group)
Secondary The score of the Epworth Sleepiness scale This scale is made up of 8 questions and the final score obtained ranges from 0 to 24: [0-6] = Absence of drowsiness; [7-9] = contentious score which may indicate a pathological condition; [10-24] = Risk of pathological drowsiness. Change from baseline (Day 0) at Month 6 (and at Month 12 only for the experimental group)
Secondary The score of the Patient Global Impression of Change (PGIC) scale This scale is used to assess the evolution of the patient's state of health in terms of activity limitation, symptoms, emotions and quality of life. This scale ranges from 1 "greatly improved" to 7 "greatly worsened", for which the patient is asked to choose the phrase that best represents the changes in his or her overall health. Change from baseline (Day 0) at Month 6 (and at Month 12 only for the experimental group)
Secondary The drug consumption, particularly analgesics, antidepressants, benzodiazepines and related hypnotics INN , dosage and duration Change from baseline (Day 0) at Month 6 (and at Month 12 only for the experimental group)
Secondary The cost-utility ratio for the medico-economic impact of the care pathway The costs avoided in terms of drug consumption, as well as changes in patients' quality of life at different stages. Change from baseline (Day 0) at Month 6
Secondary The score of the International Restless legs syndrome (IRLS) questionnaire The latter assesses the severity of RLS according to four levels: for a score between 0 and 10, the disorder is mild; between 11 and 20, moderate; between 21 and 30, severe; between 31 and 40, very severe. At the 1st sleep consultation (Month 1) then at Month 6 and Month 12
Secondary For the experimental group, the average apnea-hypopnea index (AHI) It represents the average frequency of apneas and hypopneas per hour of sleep. There are three levels of apnea and hypopnea severity. The mild degree corresponds to respiratory incidents of between 5 and 15 per hour, the moderate degree corresponds to respiratory incidents between 15 and 30 per hour, and the severe degree indicates more than 30 respiratory events per hour. at start of ventilation (continuous positive airway pressure), then for periods Month 3-Month 6 and Month 6-Month 12
Secondary For the experimental group, the score of the insomnia severity index (ISI) This validated self-questionnaire consists of 7 questions designed to assess the nature of insomnia, sleep satisfaction, day-to-day functioning and anxiety about sleep disorders. Each of the 7 items is evaluated on a 5-point Likert scale (from 0 to 4). The total score is obtained by adding together the scores of the 7 items . The total score ranges from 0 to 28: [0-7] = No insomnia; [8- 14] = Subclinical insomnia (mild); [15-21] = Clinical insomnia (moderate); [22-28] = Clinical insomnia (severe). At the 1st sleep consultation (Month 1) then at Month 6 and Month 12
See also
  Status Clinical Trial Phase
Completed NCT01659073 - Using Perfusion MRI to Measure the Dynamic Changes in Neural Activation Associated With Caloric Vestibular Stimulation N/A
Recruiting NCT05914311 - Use of Dermabond in Mitigation of Spinal Cord Stimulation (SCS) Trial Lead Migration N/A
Recruiting NCT05422456 - The Turkish Version of Functional Disability Inventory
Enrolling by invitation NCT05422443 - The Turkish Version of Pain Coping Questionnaire
Completed NCT05057988 - Virtual Empowered Relief for Chronic Pain N/A
Completed NCT04385030 - Neurostimulation and Mirror Therapy in Traumatic Brachial Plexus Injury N/A
Recruiting NCT06206252 - Can Medical Cannabis Affect Opioid Use?
Completed NCT05103319 - Simultaneous Application of Ketamine and Lidocaine During an Ambulatory Infusion Therapy as a Treatment Option in Refractory Chronic Pain Conditions
Completed NCT03687762 - Back on Track to Healthy Living Study N/A
Completed NCT04171336 - Animal-assisted Therapy for Children and Adolescents With Chronic Pain N/A
Completed NCT03179475 - Targin® for Chronic Pain Management in Patients With Spinal Cord Injury Phase 4
Completed NCT03418129 - Neuromodulatory Treatments for Pain Management in TBI N/A
Completed NCT03268551 - MEMO-Medical Marijuana and Opioids Study
Recruiting NCT06204627 - TDCS* and Laterality Trainnning in Patients With Chronic Neck Pain N/A
Recruiting NCT06060028 - The Power of Touch. Non-Invasive C-Tactile Stimulation for Chronic Osteoarthritis Pain N/A
Completed NCT05496205 - A SAD Study to Evaluate the Safety, Tolerability and PK/PD of iN1011-N17 in Healthy Volunteers Phase 1
Completed NCT00983385 - Evaluation of Effectiveness and Tolerability of Tapentadol Hydrochloride in Subjects With Severe Chronic Low Back Pain Taking Either WHO Step I or Step II Analgesics or no Regular Analgesics Phase 3
Recruiting NCT05118204 - Randomized Trial of Buprenorphine Microdose Inductions During Hospitalization Phase 4
Terminated NCT03538444 - Repetitive Transcranial Magnetic Stimulation for Opiate Use Disorder N/A
Not yet recruiting NCT05812703 - Biometrics and Self-reported Health Changes in Adults Receiving Behavioral Treatments for Chronic Pain